PublicListing.in
Comprehensive Analysis: Bio Medica Laboratories SME IPO
The Indian pharmaceutical sector continues to be a hotspot for dynamic investments. If you are tracking the SME platform for emerging opportunities, the upcoming Bio Medica Laboratories Ltd. IPO deserves your attention. Set to launch on the NSE SME board, this contract manufacturing pharma company is looking to raise capital to fund its aggressive expansion plans.
In this detailed review, we at Publiclisting.in break down everything you need to know about the Bio Medica Laboratories IPO—from business fundamentals and financial health to exact dates, valuations, and market consensus.
What Does Bio Medica Laboratories Do?
Incorporated in August 2015, Bio Medica Laboratories Ltd. has carved out a niche in the B2B pharmaceutical sector. The company operates as a dedicated contract manufacturer, developing and producing a diverse array of pharmaceutical parenteral formulations tailored to specific client requirements.
Key Highlights of their Product Portfolio:
- Liquid Injectables: A robust lineup comprising 58 distinct products.
- Dry-Powder Injectables: 15 specialized products under this vertical.
- Versatile Offerings: Availability in both single-dose and multi-dose formats catering to human and veterinary healthcare.
- Broad Spectrum: Manufacturing spans across generic drugs, branded pharmaceuticals, and Over-The-Counter (OTC) medications.
The company currently operates two state-of-the-art manufacturing facilities in Indore, Madhya Pradesh, and proudly holds Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certifications from the local FDA.
Key IPO Details at a Glance
The company is aiming to raise ₹52.43 Crores through a book-built issue. This comprises a fresh equity infusion alongside an Offer for Sale (OFS) by existing shareholders.
| Particulars | Details |
|---|---|
| Issue Type | Book Built Issue IPO |
| Total Issue Size | 37,72,000 shares (Aggregating up to ₹52.43 Cr) |
| Fresh Issue | 32,06,000 shares (Aggregating up to ₹45.00 Cr) |
| Offer for Sale (OFS) | 3,77,000 shares (Aggregating up to ₹5.24 Cr) |
| Price Band | ₹132 to ₹139 per equity share |
| Face Value | ₹10 per share |
| Listing Exchange | NSE SME |
IPO Schedule & Timeline (Tentative)
Timing is crucial when participating in an IPO. Below is the step-by-step timeline for the Bio Medica Laboratories offering. Keep these dates marked to ensure you don't miss the bidding window.
Lot Size & Investment Requirements
To accommodate different tiers of investors, the lot size has been structured accordingly. A single lot consists of 1,000 shares, but retail investors must bid for a minimum of 2 lots.
| Investor Category | Minimum Lots | Total Shares | Investment Amount (at Upper Band) |
|---|---|---|---|
| Retail Investor (Min/Max) | 2 Lots | 2,000 Shares | ₹2,78,000 |
| Small HNI (Min) | 3 Lots | 3,000 Shares | ₹4,17,000 |
| Big HNI (Min) | 8 Lots | 8,000 Shares | ₹11,12,000 |
Financial Performance Analysis
A closer look at the restated financials reveals a company on a steep growth trajectory. Between FY23 and FY25, total income more than doubled, while Profit After Tax (PAT) witnessed a massive leap, showcasing improved operational efficiencies and margins.
| Financial Metric (₹ in Crores) | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Total Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax (PAT) | 8.66 | 9.79 | 2.50 | 0.33 |
| Net Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Note: The surge in borrowings up to Nov 2025 highlights the need for capital restructuring, which aligns with their IPO objectives.
Valuation & Key Performance Indicators (KPIs)
Understanding the valuation metrics is vital to gauge if the issue is priced reasonably. As per the latest FY25 data available in the draft papers:
Valuation Multiples
- Pre-IPO P/E Ratio: 13.03x
- Post-IPO P/E Ratio: 13.45x
- Pre-IPO Market Cap: ₹174.79 Cr
- Price to Book Value: 8.66
Efficiency Ratios (Mar 2025)
- Return on Equity (ROE): 99.59%
- Return on Capital Employed (ROCE): 48.20%
- EBITDA Margin: 39.83%
- Debt to Equity: 1.02
Objectives of the Issue
Transparency regarding fund utilization is a hallmark of a fundamentally sound IPO. Bio Medica intends to deploy the net proceeds (approx. ₹35.00 Cr from the fresh issue) toward the following pivotal objectives:
- Capacity Expansion (₹28.50 Cr): Setting up a brand-new manufacturing facility within their existing premises to scale up production capabilities.
- Debt Reduction (₹6.50 Cr): Repayment of existing loans, which will immediately improve the balance sheet and reduce finance costs.
- General Corporate Purposes: Funding day-to-day operational needs and strategic initiatives.
Promoter Holding & Issue Reservation
The company is steered by experienced promoters, Mr. Mukesh Mehta and Mr. Pradeep Mehta. Prior to the IPO, they hold a commanding 99.99% stake in the company. Post-issue dilution will bring public shareholders on board, aiding in corporate governance and wealth distribution.
| Investor Category | Reservation Allocation | Number of Shares |
|---|---|---|
| Retail Individual Investors (RII) | 50.01% | 17,92,000 |
| Non-Institutional Investors (HNI) | 48.98% | 17,55,000 |
| Qualified Institutional Buyers (QIB) | 1.00% | 36,000 |
| Market Maker | Firm Reservation | 1,89,000 |
SWOT Analysis of Bio Medica Laboratories
Before applying, it is prudent to weigh the internal and external factors affecting the business through a SWOT perspective:
Strengths
- Diversified product portfolio of over 70 injectables.
- GMP & GLP certified manufacturing facilities.
- Exceptional surge in ROE and PAT in recent fiscal years.
Weaknesses
- High dependence on the B2B contract manufacturing model.
- Recent spike in total borrowings (pre-IPO).
Opportunities
- Proceeds will fund a new facility, drastically increasing production volume.
- Growing domestic and global demand for generic and OTC parenterals.
Threats
- Intensely competitive and fragmented SME pharma sector.
- Stringent regulatory shifts from health authorities (FDA).
Market Consensus & Verdict
Bio Medica Laboratories is operating within a highly competitive segment of contract pharma manufacturing. However, the sheer leap in their top-line and bottom-line numbers between FY23 and FY25 cannot be ignored. The asking price reflects these aggressive growth metrics, meaning the IPO appears fully priced.
General market sentiment suggests that while the fundamentals look promising due to the planned capacity expansion and debt repayment, investors should approach this with a medium-to-long-term horizon. Risk-tolerant investors looking to diversify into the SME healthcare space might find this an interesting proposition.
Important Contact & Registrar Details
For any queries related to allotment, refund status, or application tracking, investors must contact the official registrar to the issue.
Registrar Info
Skyline Financial Services Pvt.Ltd.
Phone: 022-28511022
Email: ipo@skylinerta.com
Company Contact
Bio Medica Laboratories Ltd.
Plot No. 11B-11C, Sector-E, Sanwer Road
Industrial Area, Indore, MP - 452015
Email: companysecretary@biomedica.co.in
Lead Manager
Narnolia Financial Services Ltd.
Disclaimer: The information provided in this blog is for educational and informational purposes only. It does not constitute financial advice. Investing in SME IPOs carries inherent risks. Please consult with a certified financial advisor before making any investment decisions.